Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib vs Sotorasib or Adagrasib in KRAS G12C+ NSCLC
NCT06497556Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of divarasib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Sep 2024; status: active, not recruiting.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06497556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497556.